- 产品描述
- 产品组分
- 文件资源
- 营销中心
- 注意事项
- FAQ
- 文献追踪
-
地西他滨(也称为 Deoxycytidine;5-aza-dCyd;NSC 127716;5-Aza-2'-deoxycytidine;deoxyazacytidine;dezocitidine;商品名:Dacogen。缩写:5AZA;DAC)是一种有效的口服生物活性抑制剂。DNA 甲基化(DNA 甲基转移酶)通常用于治疗骨髓增生异常综合征 (MDS) 和急性髓系白血病 (AML)。地西他滨是一种脱氧胞苷类似物,是细胞分化的诱导剂。地西他滨在体外重新激活表观遗传沉默的肿瘤抑制基因方面已显示出显着功效。在 T24 膀胱癌细胞中,地西他滨可以增加未甲基化 p14 启动子处的组蛋白 H3-赖氨酸 9 乙酰化和组蛋白 H3-赖氨酸 4 甲基化。
靶点 DNMT1; DNMT3A; DNMT3B
体外研究 (In Vitro) 接触地西他滨 96 小时后,地西他滨治疗显着降低了 SNU719、NCC24 和 KATOIII 的细胞增殖。地西他滨导致 EBVaGC 中 G2/M 期停滞和死亡,降低侵袭能力,并上调 EBVaGC 中 E-钙粘蛋白表达 [1]。只有高剂量 (10 μM) 地西他滨(0.1-1 μM;24-72 小时)才会产生 G2 期停滞,并伴有 G1 细胞减少 [3]。地西他滨上调 HeLa 细胞中的 DCTPP1 和 dUTPase 表达 [4]。
体内研究 (In Vivo) 在雌性 CD-1 小鼠中,地西他滨(1.0 mg/kg,口服)与四氢尿苷(THU)联合使用会导致严重毒性,并增加与地西他滨血浆水平相关的地西他滨毒性的易感性[5]。已建立 EL4 肿瘤的 C57BL/6 小鼠在给予地西他滨(1.0 mg/kg;腹腔注射;每天一次,持续 5 天)后显示出消退 [7]。
酶活实验 掺入测定[8]
处理前24小时,将细胞一式三份接种在12孔板中,密度为每孔2×105个细胞,然后与100nM[3H]-地西他滨(或其他浓度,如有指示)一起孵育。孵育24小时(或其他时间段,如果需要)后,用磷酸盐缓冲盐水(PBS)洗涤细胞。对于掺入测量,分别使用DNeasy血液和组织试剂盒或RNeasy试剂盒纯化DNA或RNA,并通过紫外线(UV)光度计进行定量。将纯化的样品与液体闪烁混合物混合,并通过液体闪烁计数测量其放射性。将测量值标准化为DNA(或RNA)的量。如前所述,地西他滨对胞嘧啶的取代百分比计算为作为总胞嘧啶的一部分引入的地西他宾的量。对于竞争实验,细胞要么用100nM[3H]-地西他滨加上增加浓度(100nM,500nM,1μM,2μM)的[14C]-脱氧胞苷处理,要么用100nm[14C]--脱氧胞苷加上增加的[3H]--地西他宾浓度(100nm,500nM,1μM,2μM)处理。24小时后,用PBS洗涤细胞,使用DNeasy血液和组织试剂盒提取DNA,并使用液体闪烁计数进行测量
DNA甲基化分析[8]
使用DNeasy血液和组织试剂盒从细胞中分离基因组DNA。如前所述,通过毛细管电泳测定全局DNA甲基化水平。细胞实验 细胞周期分析[1]
细胞类型: HCT116 细胞
测试浓度: 0.1、1、10 µM
孵育时间: 24、48、72 小时
实验结果: 只有高药物浓度 (10 µM) 才会导致 G2 期停滞,同时伴随着 G1 期细胞的减少阶段。动物实验 Animal/Disease Models: C57BL/6 mice (bearing EL4 cells)[6]
Doses: 1.0 mg/kg
Route of Administration: intraperitoneal (ip)injection; one time/day for 5 days consecutive
Experimental Results: Caused continuous tumor regression even after Decitabine treatment was stopped.药代性质 (ADME/PK) Absorption
Decitabine administered intravenously at 15 mg/m2 for three hours every eight hours over three days resulted in a Cmax of 73.8 ng/mL (66% coefficient of variation, CV), an AUC0-∞ of 163 ng\*h/mL (62% CV), and a cumulative AUC of 1332 ng\*h/mL (95% CI of 1010-1730). Similarly, decitabine at 20 mg/m2 for one hour once daily over five days resulted in a Cmax of 147 ng/mL (49% CV), an AUC0-∞ of 115 ng\*h/mL (43% CV), and a cumulative AUC of 570 ng\*h/mL (95% CI of 470-700).
Route of Elimination
Less than 1% of administered decitabine is excreted in the urine.
Volume of Distribution
Decitabine as an apparent volume of distribution of 4.59 ± 1.42 L/kg.
Clearance
Decitabine has a clearance of 125 L/hr/m2 (53% CV) when administered intravenously at 15 mg/m2 for three hours every eight hours over three days, and a clearance of 210 L/hr/m2 (47% CV) at 20 mg/m2 for one hour once daily over five days.
Metabolism / Metabolites
Decitabine is phosphorylated inside cells by the sequential action of deoxycytidine kinase, nucleotide monophosphate kinase, and nucleotide diphosphate kinase, prior to being incorporated into newly synthesized DNA by DNA polymerase. Decitabine not incorporated into cellular DNA undergoes deamination by cytidine deaminase followed by additional degradation prior to excretion.
Biological Half-Life
Decitabine has a half-life of 0.62 hours (49% CV) when administered intravenously at 15 mg/m2 for three hours every eight hours over three days, and a half-life of 0.54 hours (43% CV) at 20 mg/m2 for one hour once daily over five days.毒性/毒理 (Toxicokinetics/TK) Hepatotoxicity
In early clinical trials using high doses of decitabine, serum enzyme elevations occurred in up to 16% of patients with underlying liver disease or liver metastases, but rarely in persons without hepatic illness. In subsequent studies, serum ALT elevations were reported in 5% to 15% of treated patients, but all were self-limited and no clinically apparent liver injury was reported. Recent studies have reported elevations in serum bilirubin levels in 7% to 12% of treated patients, but the elevations resolved rapidly and were not associated with other clinical or laboratory evidence of liver injury. Monitoring of serum enzyme levels during treatment is recommended only in patients with concurrent liver disease.
The oral combination therapy of decitabine with cedazuridine appears to have a similar frequency and pattern of adverse events as iv decitabine alone. In several prospective clinical trials, single cycles of oral vs iv decitabine had similar rates of aminotransferase elevations and long term, multi-course regimens of the oral fixed dose combination therapy resulted in serum aminotransferase elevations in 20% to 37% of patients, which were above 5 times the upper limit of normal (ULN) in 2% to 3% with no cases of clinically apparent liver injury attributable to the chemotherapeutic agent.
Thus, despite widescale use as therapy of MDS, decitabine has not been convincingly linked to cases of clinically apparent liver injury. Nevertheless, the frequency of serum enzyme elevations with therapy make it difficult to say that decitabine is totally without potential for causing drug induced liver injury.
Likelihood score: E* (unproven but suspected, rare cause of clinically apparent liver injury).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. It might be possible to breastfeed safely during intermittent decitabine therapy with an appropriate period of breastfeeding abstinence; the manufacturer recommends an abstinence period of 1 week after the last dose. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk. Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
A telephone follow-up study was conducted on 74 women who received cancer chemotherapy at one center during the second or third trimester of pregnancy to determine if they were successful at breastfeeding postpartum. Only 34% of the women were able to exclusively breastfeed their infants, and 66% of the women reported experiencing breastfeeding difficulties. This was in comparison to a 91% breastfeeding success rate in 22 other mothers diagnosed during pregnancy, but not treated with chemotherapy. Other statistically significant correlations included: 1) mothers with breastfeeding difficulties had an average of 5.5 cycles of chemotherapy compared with 3.8 cycles among mothers who had no difficulties; and 2) mothers with breastfeeding difficulties received their first cycle of chemotherapy on average 3.4 weeks earlier in pregnancy. Of the 9 women who received a fluorouracil-containing regimen, 8 had breastfeeding difficulties.
Protein Binding
Decitabine exhibits negligible (< 1%) plasma protein binding.参考文献 [1]. Nakamura M, et al. Decitabine inhibits tumor cell proliferation and up-regulates E-cadherin expression in Epstein-Barr virus-associated gastric cancer. J Med Virol. 2016 Jul 19.
[2]. Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev. 2009 Jul;109(7):2880-93.
[3]. Hagemann S, et al. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011 Mar 7;6(3):e17388.
[4]. Requena CE, et al. The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine. Biochem J. 2016 Jun 20.
[5]. Terse P, et al. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33(2):75-85.
[6]. Yu J, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest. 2018 Jun 1;128(6):2376-2388.
[7]. Wang LX, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumorspecific cytotoxic T lymphocyte responses. PLoS One. 2013 May 9;8(5):e62924.
[8]. Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells. Nucleic Acids Res. 2014 Oct 29; 42(19): e152.其他信息 5-aza-2'-deoxycytidine is a fine white crystalline powder. Used as a drug.
5-aza-2'-deoxycytidine is a 2'-deoxyribonucleoside.
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment options, nucleoside analogues such as decitabine and [azacitidine] integrate into cellular DNA and inhibit the action of DNA methyltransferases, leading to global hypomethylation and related downstream therapeutic benefits. Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. It was first marketed under the name Dacogen®. It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine].
Decitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of decitabine is as a Nucleic Acid Synthesis Inhibitor.
Decitabine is a cytosine analogue and an intravenously administered antineoplastic agent used in the therapy of myelodysplastic syndromes. Decitabine is associated with a low rate of transient serum enzyme elevations during therapy, but has not been implicated in causing clinically apparent liver injury with jaundice.
Decitabine is a cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)
An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA.*注: 文献方法仅供参考, IVDSHOW并未独立验证这些方法的准确性。
分子式 C8H12N4O4分子量 228.21精确质量 228.085元素分析 C, 42.10; H, 5.30; N, 24.55; O, 28.04CAS号 2353-33-5相关CAS号 2353-33-5 PubChem CID 451668外观&性状 White to off-white solid密度 1.9±0.1 g/cm3沸点 485.8±55.0 °C at 760 mmHg熔点 ~200 °C (dec.)闪点 247.6±31.5 °C蒸汽压 0.0±2.8 mmHg at 25°C折射率 1.780LogP -1.93tPSA 123.49SMILES O1[C@]([H])(C([H])([H])[C@@]([H])([C@@]1([H])C([H])([H])O[H])O[H])N1C([H])=NC(N([H])[H])=NC1=OInChi Key XAUDJQYHKZQPEU-KVQBGUIXSA-NInChi Code InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1化学名 4-amino-1-((2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one别名 5-Aza-2'-deoxycytidine; deoxyazacytidine; 2353-33-5; Dacogen; 2'-Deoxy-5-azacytidine; 5-Azadeoxycytidine; AzadC; 5-aza-CdR; 5-aza-dCyd; Deoxycytidine; NSC127716; NSC 127716; NSC-127716; dezocitidine; Brand name: Dacogen. Abbreviations: 5AZA; DACHS Tariff Code 2934.99.9001存储方式 Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Note: This product requires protection from light (avoid light exposure) during transportation and storage. -
产品组分
内容 型号 规格 储存温度
地西他滨Decitabine(NSC-127716) V19260-01 5mg -20°C 地西他滨Decitabine(NSC-127716) V19260-02 10mg -20°C 地西他滨Decitabine(NSC-127716) V19260-03 100mg -20°C 地西他滨Decitabine(NSC-127716) V19260-04 250mg -20°C 地西他滨Decitabine(NSC-127716) V19260-05 500mg -20°C 地西他滨Decitabine(NSC-127716) V19260-06 1g -20°C 地西他滨Decitabine(NSC-127716) V19260-07 2g -20°C 操作手册
1 1 常温
-
文件资源
文件下载 文件内容 资源说明 
V19260-地西他滨Decitabine(NSC-127716) 操作手册 
V19260-地西他滨Decitabine(NSC-127716)相关单页 宣传单页 -
注意事项
保存建议 厂家推荐蓝冰运输。当您收到产品后,按照说明书建议保存于-20°C。 -
FAQ

-
[1] J. Integr. Neurosci. 2024, 23(9), 181
[2] US20230172936A1.
猜你喜欢
在线留言
如果您对我们的产品感兴趣,请留下您的信息,我们将尽快与您联系,谢谢!
艾维缔官网
艾德官网
B站IVDSHOW
抖音军哥聊表观
视频号艾维缔
小红书艾维缔
快手表观盒子
表观遗传学
联系我们
